Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma

被引:0
作者
Yi-yun Yao
Yong Tang
Yan Zhuang
Li-fang Zou
Hong-ju Dou
Lei Wang
Qi Zhu
机构
[1] Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Department of Hematology
来源
Indian Journal of Hematology and Blood Transfusion | 2017年 / 33卷
关键词
Extranodal NK/T cell lymphoma; Induction chemotherapy; Pegaspargase; Gemicitabine; Oxaliplatin; Prognostic factors;
D O I
暂无
中图分类号
学科分类号
摘要
This study was conducted to retrospectively investigate the efficacy and safety of pegaspargase, gemicitabine, oxaliplatin and dexamethasone (Peg-GemOD) combination chemotherapy as a first-line therapy for advanced-stage extranodal NK/T cell lymphoma (ENKTL). Eighteen patients with newly diagnosed stage III/IV ENKTL were subjected to 3–6 cycles of Peg-GemOD chemotherapy. After 3 cycles of therapy, the overall response rate was 67 % (12/18) with a complete response rate of 28 % (5/18) and a partial response rate of 39 % (7/18). The median overall survival (OS) and progression-free survival (PFS) time were 10 and 8.5 months respectively. For those responders, the median OS and PFS time were significantly better than those of non-responders (median OS, 15 vs. 10 months; P = 0.001 and median PFS, 15 vs. 7 months; P = 0.001). Furthermore, patients with low plasma EBV-DNA levels after induction chemotherapy had a remarkably longer OS and PFS time. The toxicity of Peg-GemOD regimen was acceptable.
引用
收藏
页码:74 / 81
页数:7
相关论文
共 60 条
[1]  
Aozasa K(2008)Nasal NK/T-cell lymphoma: epidemiology and pathogenesis Int J Hematol 87 110-117
[2]  
Takakuwa T(2013)First-line combination of gemcitabine, oxaliplatin, and Cancer 119 348-355
[3]  
Hongyo T(2012)-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma J Clin Oncol 30 4044-4046
[4]  
Wang L(1995)Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211 Cancer 76 2351-2356
[5]  
Wang ZH(2011)Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells Blood 117 1834-1839
[6]  
Chen XQ(2014)GELA and GOELAMS Intergroup. Efficacy of Ann Hematol 93 1889-1894
[7]  
Yamaguchi M(2012)-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study Blood 120 2973-2980
[8]  
Tobinai K(2013)Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients Investig New Drugs 31 469-472
[9]  
Oguchi M(2013)SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group Leuk Lymphoma 54 1194-1200
[10]  
Yamaguchi M(2012)Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma Curr Pharm Des 18 2811-2829